Watch CBS News

Mexico: Reputed Drug Queen Gets Botox in Prison

MEXICO CITY - Bars and barbed wire couldn't keep a reputed Mexican drug cartel "queen" from getting Botox in prison, authorities said Tuesday.

Mexico City's prison authority says a doctor was improperly admitted to Santa Martha Acatitla women's lockup in January to perform what it called a "procedure not authorized for inmates."

City prosecutors later said in a statement that the doctor gave a Botox injection to Sandra Avila Beltran, a purported top decision-maker in the Sinaloa cartel better known as the "Queen of the Pacific."

Avila Beltran has been in custody since 2007 on suspicion of conspiracy to traffic drugs, money laundering and organized crime. A judge acquitted her of the charges in December, but prosecutors are appealing that ruling.

She also faces possible extradition to the United States in connection with the 2001 seizure of more than 9 tons of U.S.-bound cocaine aboard a fishing vessel in the port of Manzanillo, along Mexico's west coast.

Avila Beltran has denied the allegations and says she made her money selling clothes and renting houses.

At the time of her arrest, her boyfriend was suspected Colombian trafficker Juan Diego Espinoza Ramirez. Prosecutors said Avila Beltran spent more than a decade working her way to the top of Mexico's drug trade, seducing several notorious kingpins and uniting Colombian and Mexican gangs.

Officers began tracking Avila Beltran closely in Mexico City, where she dined at a pricey Thai restaurant and had manicures in ritzy salons frequented by TV stars. The story of her arrest enthralled Mexicans, inspiring a "narcocorrido" folk ballad.

Security in Mexican prisons is frequently lax and corruption often allows contraband to be smuggled inside.

The prison authority said the facility's warden and medical director were fired.

Authorities are investigating the case.

View CBS News In
CBS News App Open
Chrome Safari Continue
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.